论文部分内容阅读
目的:分析通窍活血汤加减联合西药对人脑胶质瘤患者预后及安全性的影响,为临床治疗及相关研究提供参考。方法:将66例符合研究标准的人脑胶瘤患者随机分为治疗组和对照组。对照组予替莫唑胺胶囊治疗,治疗组在对照组治疗的基础上予通窍活血汤加减治疗。连续治疗2个疗程后观察比较两组临床疗效、患者的预后及治疗的安全性等数据。结果:总有效率治疗组为78.8%,对照组为54.5%,治疗组优于对照组,差异有统计学意义(P<0.05);治疗组不良反应发生率为18.2%,对照组不良反应发生率为42.4%,治疗组低于对照组(P<0.05);治疗组复发率为36.4%,对照组复发率为45.5%,治疗组低于对照组(P<0.05)。治疗后两组KPS评分均优于治疗前(P<0.05);治疗后治疗组KPS评分高于对照组,差异有统计学意义(P<0.05)。结论:通窍活血汤加减联合西药治疗人脑胶质瘤疗效显著,可降低复发率,改善患者的生活质量。
Objective: To analyze the effect of Tongqiao Huoxue Decoction combined with western medicine on the prognosis and safety of human glioma patients, and provide references for clinical treatment and related research. Methods: Sixty-six human brain tumor patients who met the research criteria were randomly divided into treatment group and control group. The control group was treated with temozolomide capsules, and the treatment group was treated with Tongqiaohuoxue Decoction on the basis of the control group. After two courses of continuous treatment, the clinical efficacy, the prognosis of patients and the safety of treatment were observed and compared. Results: The total effective rate was 78.8% in the treatment group and 54.5% in the control group. The treatment group was superior to the control group with statistically significant difference (P <0.05). The incidence of adverse reactions in the treatment group was 18.2%, and the adverse reactions in the control group The treatment group was lower than the control group (P <0.05). The recurrence rate was 36.4% in the treatment group and 45.5% in the control group. The treatment group was lower than the control group (P <0.05). After treatment, the KPS scores of both groups were better than those before treatment (P <0.05). The KPS scores of the treatment group were higher than those of the control group after treatment (P <0.05). Conclusion: Tongqiao Huoxue Decoction combined with Western medicine treatment of human glioma significant effect, can reduce the recurrence rate and improve the quality of life of patients.